T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis

BACKGROUND: Current guidelines consider T-DM1 the standard 2(nd) line therapy for HER2 positive metastatic breast cancer (MBC) patients following trastuzumab (T) + pertuzumab (P) and taxane 1(st) line treatment. Despite this, there are no prospective studies supporting this sequence. METHODS: We per...

Descripción completa

Detalles Bibliográficos
Autores principales: Omarini, Claudia, Piacentini, Federico, Sperduti, Isabella, Cerma, Krisida, Barbolini, Monica, Canino, Fabio, Nasso, Cecilia, Isca, Christel, Caggia, Federica, Dominici, Massimo, Moscetti, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9172020/
https://www.ncbi.nlm.nih.gov/pubmed/35672679
http://dx.doi.org/10.1186/s12885-022-09556-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9172020/
https://www.ncbi.nlm.nih.gov/pubmed/35672679
http://dx.doi.org/10.1186/s12885-022-09556-7

Ejemplares similares